Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study
ConclusionsThis study highlights the importance of monitoring injection-related injuries and transient deafness events in patients treated with nusinersen. For onasemnogene abeparvovec, careful monitoring for renal impairment, liver injury, and myocardial damage is necessary. Risdiplam requires attention to the potential risk of rare but severe gastrointestinal damage events and hypoglycemia. Importantly, risdiplam exhibited lower liver and renal toxicity, making it a potential consideration for patients with liver or renal insufficiency or for combined use with other drugs that possess high liver or renal toxicity. These ...
Source: Clinical Drug Investigation - November 23, 2023 Category: Drugs & Pharmacology Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
CONCLUSION: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.PMID:37992742 | PMC:PMC10681826 | DOI:10.3349/ymj.2023.0080 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - November 22, 2023 Category: Universities & Medical Training Authors: Hui Jin Shin Ji-Hoon Na Hyunjoo Lee Young-Mock Lee Source Type: research
